An accessible explanation of how GLP-1 drugs like Ozempic and Wegovy actually work — the biology of appetite, satiety, and why these medications are transforming obesity treatment.
GLP-1 medications — Ozempic, Wegovy, Mounjaro, Zepbound — are dominating headlines. But what are they actually doing in your body? Understanding the biology makes the treatment make much more sense.
GLP-1 (glucagon-like peptide-1) is a hormone your body naturally produces in the cells lining your small intestine — specifically a type of cell called L-cells. You release GLP-1 naturally when you eat, particularly in response to carbohydrates and fats.
GLP-1 is one of your body's "I just ate" signals. It coordinates multiple systems simultaneously to manage the incoming nutrients and tell your brain the meal is complete.
When GLP-1 is released after a meal, it acts on multiple organs at once:
GLP-1 stimulates beta cells to release insulin (the hormone that moves glucose from blood into cells) and suppresses glucagon (which normally raises blood sugar). This is why GLP-1 drugs were developed for diabetes first — they improve blood sugar management. Critically, this happens in a glucose-dependent way, meaning GLP-1 only triggers insulin when blood sugar is actually elevated. This is why GLP-1 drugs rarely cause hypoglycemia unlike older diabetes medications.
GLP-1 slows gastric emptying — the rate at which food moves from your stomach into the small intestine. A slower-emptying stomach creates prolonged feelings of fullness. This is also the primary cause of GLP-1 nausea: eating too much too fast creates backup when the stomach is moving slowly.
This is where the weight loss really happens. GLP-1 receptors exist in the hypothalamus (the brain's appetite control center) and the brainstem. When activated, they reduce appetite and food cravings — not just making you less hungry, but reportedly reducing the reward and pleasure signals associated with highly palatable foods. Many patients report that food simply becomes less interesting.
Your natural GLP-1 has a half-life of only about 2 minutes — it's rapidly broken down by enzymes in your bloodstream. This is biologically appropriate for a meal-response signal, but means it can't provide sustained appetite suppression.
Pharmaceutical GLP-1 receptor agonists are modified to be resistant to this degradation. Semaglutide has a half-life of about 7 days (hence weekly injections). Tirzepatide: about 5 days. This sustained receptor activation is what provides continuous appetite suppression between doses.
Newer drugs activate additional receptor systems beyond GLP-1:
GLP-1 medications don't cure obesity — they manage it. When the drug is discontinued, GLP-1 receptor activation returns to baseline (your natural 2-minute pulses post-meal), appetite returns, and the hunger that was suppressed reasserts itself. This is why STEP 4 trial data showed ~2/3 of weight lost returning within 1 year of stopping semaglutide.
This is now understood as analogous to blood pressure medication — effective while taken, requiring ongoing use for sustained effect.